Ranbaxy launches urology drug Roliflo OD based on multiparticulate technology

Ranbaxy Laboratories Limited has launched Roliflo OD (combination of tamsulosin and tolterodine) brand in the Indian market for the management of "bladder outlet obstruction with concomitant overactive bladder", a chronic urological disorder.

This is a novel drug delivery system (NDDS) product, which is being introduced for the first time in India.

Roliflo OD will be sold as a once-a-day combination of tolterodine tartarate extended release 4mg and tamsulosin hydrochloride extended release 0.4mg dosage capsules.

"Roliflo OD will provide the urologists with an improved treatment option for patients suffering from this highly uncomfortable condition," said Sanjeev Dani, Sr. VP and regional director, Asia and CIS, Ranbaxy. "Ranbaxy is the leader in the urology segment and the introduction of Roliflo OD based on our proprietary multiparticulate NDDS technology further reinforces our leadership position in delivering novel therapeutic options, to urologists in the Indian market," Dani added.

Overactive bladder in patients with bladder outlet obstruction largely remains under-treated due to the occurrence of side effects with currently available options in such patients. Roliflo OD has demonstrated clinical tolerability of antimuscarinics during various clinical trials due to the specially designed NDDS profile of the product.

The extended release of the medicine in the human body is made possible because of the polymer coated beads of tolterodine tartrate and tamsulosin hydrochloride, that are packed in a capsule, to enable only once a day administration. This significantly enhances patient convenience and improves compliance.

Five out of every ten individuals above 40 years are believed to suffer from benign prostatic hyperplasia (enlarged prostate) with concomitant overactive bladder (OAB). The problem is common among men in both rural and urban population.